Results 31 to 40 of about 4,801,388 (251)

The Prevention of Hereditary Breast and Ovarian Cancer: A Personal View

Hereditary Cancer in Clinical Practice, 2004
Options for the prevention of hereditary breast and ovarian cancer include screening, preventive surgery and chemoprevention. Screening studies with magnetic resonance imaging of the breast are promising but the technology is not widespread and MRI is ...
Narod Steven
doaj   +1 more source

Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis [PDF]

, 2018
Bivalent chromatin domains containing both active H3K4me3 and repressive H3K27me3 histone marks define gene sets poised for expression or silencing in differentiating embryonic stem (ES) cells.
Edward Curry, Zeller, C, Bowtell, DD, Bowtell, David, Curry, Edward, Wilhelm-Benartzi, Charlotte S., Wilhelm-Benartzi, CS, Patten, DK, Wilhelm-Benartzi, Charlotte, Nahal Masrour, John Gallon, Gallon, J, Zeller, Constanze, Sadaf Ghaem-Maghami, Ghaem-Maghami, S, David D. Bowtell, Masrour, N, Robert Brown, Constanze Zeller, Curry, E, Brown, Robert, Gallon, John, Ghaem-Maghami, Sadaf, Patten, Darren, Brown, R, Patten, Darren K., Bowtell, David D., Masrour, Nahal, Charlotte S. Wilhelm-Benartzi, Darren K. Patten   +29 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response

Journal of Experimental & Clinical Cancer Research
Background Ovarian cancers are the second cause of death from gynecological cancers worldwide, due to a late diagnosis combined with the development of resistance to chemotherapy.
Lucie Thorel, Enora Dolivet, Pierre-Marie Morice, Romane Florent, Jordane Divoux, Marion Perréard, Lucie Lecouflet, Guillaume Desmartin, Chloé Marde Alagama, Florence Giffard, Alexandra Leconte, Justine Lequesne, Bénédicte Clarisse, Mélanie Briand, Alimatou Traoré, Céline Villenet, Jean-Pascal Meneboo, Guillaume Babin, Léopold Gaichies, Sandrine Martin-Françoise, Jean-François Le Brun, Roman Rouzier, Emilie Brotin, Christophe Denoyelle, Nicolas Vigneron, Raphaël Leman, Dominique Vaur, Laurent Castera, Cécile Blanc-Fournier, Nicolas Elie, Benoit Plancoulaine, Florence Joly, Matthieu Meryet-Figuière, Martin Figeac, Louis-Bastien Weiswald, Laurent Poulain   +35 more
doaj   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Prevention and early detection of prostate cancer. [PDF]

, 2014
Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer.
Culig, Zoran, Vecchia, Carlo La, Stenzl, Arnulf, P. H. Brown, Meyskens, FL, H. Schmid, Thorat, M.A., Parnes, Howard L., Wilt, Timothy J, Rittenhouse, H., Minasian, Lori M, Perner, S. (Sven), Schmid, H-P, Cuzick, J, Minasian, LM, Brawley, Otis W., Ford, Leslie G., G. Andriole, Perner, S, Key, Timothy J., D. Ilic, Ilic, Dragan, Parker, C. (C.), Key, TJ, Andriole, Gerald, Hamdy, Freddie C., R. A. Eeles, Holmberg, Lars, J. Schalken, Eeles, R. (Rosalind), Parker, C, Lilja, Hans, Wolk, Alicja, Holmberg, Lars,, Parnes, Howard L, Tombal, B, T. J. Wilt, Schmitz-Dräger, Bernd J., Schmitz-Draeger, BJ, F. H. Schröder, Hamdy, Freddie C, F. C. Hamdy, Lilja, H, Marberger, Michael, Lund University., Hamdy, FC, Schalken, J, Andriole, G.L. (Gerald), Andriole, G, Cuzick, Jack, Hamdy, F. (Freddie), Schmid, HP, Vecchia, C. La, Schmid, Hans Peter, Ford, L.G., A. Wolk, Tombal, Bertrand, Schmid, H.P., Meyskens, F.L. (Frank L), Wilt, TJ, Schmid, H.-P. (Hans-Peter), Thorat, Mangesh A, Brawley, O.W., T. J. Key, Lilja, H., Schalken, J.A. (Jack), Parker, C., Holmberg, L, Schmitz-Dräger, Bernd J, M. Marberger, La Vecchia, C, Key, T.J. (Timothy J), Brawley, OW, F. L. Meyskens, Eeles, Rosalind A, Schröder, F.H. (Fritz), B. J. Schmitz Dräger, Brown, PH, Parker, Chris, Ilic, D, Ilic, D. (Dragan), Ford, L.G. (Leslie G), C.La Vecchia, Wolk, K. (Kerstin), Tombal, B. (Bertrand), Schmitz-Drager, B.J., Minasian, L.M. (Lori M), L. M. Minasian, Schröder, Fritz H, H. Lilja, B. Tombal, Schalken, J.A., Brown, Powel H, Rittenhouse, H. (Harry), O. W. Brawley, Stenzl, A, C. Parker, Brawley, O.W. (Otis W), Meyskens, Frank L., Vecchia, C.L. (Carlo La), Culig, Z., Brown, P.H., Parnes, HL, Cuzick, J., Wilt, Timothy J., Ford, Leslie G, Z. Culig, Culig, Z. (Zoran), L. G. Ford, Brawley, Otis W, Key, Timothy J, Schmitz-Dräger, B.J. (Bernd J), S. Perner, Marberger, M, Schalken, Jack, Thorat, M.A. (Mangesh A), Hamdy, F.C., Stenzl, A. (Arnulf), Wilt, T.J., Wolk, A, Schroder, F.H., Culig, Z, Key, T.J., Eeles, R.A., Lilja, Hans,, Ford, LG, Lilja, H. (Hans), Parnes, H.L. (Howard L), Eeles, RA, Marberger, M., Andriole, G., Schröder, Fritz H., Schmid, Hans-Peter, Stenzl, A., L. Holmberg, Meyskens, F.L., Thorat, Mangesh A., A. Stenzl, Meyskens, Frank L, Brown, P.H. (Powel H), J. Cuzick, La Vecchia, Carlo, H. Rittenhouse, H. L. Parnes, Wolk, A., Rittenhouse, Harry, Perner, Sven, M. A. Thorat, Tombal, B., Schröder, Fritz, Minasian, Lori M., Ilic, D., Minasian, L.M., Parnes, H.L., Rittenhouse, H, Marberger, M. (Michael), Perner, S., Holmberg, L. (Lars), Cuzick, J. (Jack), Wilt, T.J. (Timothy J.), Holmberg, L., Thorat, MA, Eeles, Rosalind A., Brown, Powel H., Marberger M, Schmid HP, Wolk A, Cuzick J, Eeles RA, Ford LG, Ilic D, Key TJ, Stenzl A, Thorat MA, Schalken J, Hamdy FC, Parnes HL, Holmberg L, Schröder FH, Minasian LM, Parker C, Brawley OW, Andriole G, Culig Z, Schmitz-Dräger BJ, Lilja H, Rittenhouse H, La Vecchia C, Tombal B, Perner S, Wilt TJ, Meyskens FL, Brown PH, Schroder, FH, Schmitz-Drager, BJ   +194 more
core   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors

BMC Cancer
Background Combination of chemotherapy and immunotherapy is the current standard of care for advanced endometrial cancer. However, survival outcome remains poor, highlighting the urgent need for new treatments and reliable tools to identify patients who ...
Gwenn Le Gall, François Cherifi, Jordane Divoux, Romane Florent, François Christy, Alexandra Leconte, Chankannira San, Amélie Devillers, Guillaume Desmartin, Lucie Lecouflet, Bénédicte Clarisse, Samantha Ballesta, Lucie Thorel, Brice Dubois, Valentin Harter, Nathalie Rousseau, Léopold Gaichies, Sandrine Martin-Françoise, Jean-François Le Brun, Enora Dolivet, Roman Rouzier, Corinne Jeanne, Cécile Blanc-Fournier, Martin Figeac, Raphaël Leman, Laurent Castera, Laurent Poulain, Louis-Bastien Weiswald, Florence Joly   +28 more
doaj   +1 more source